National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Pembrolizumab (Keytruda®) for colorectal cancer. HTA ID: 21002

Pembrolizumab is indicated as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer in adults.

 

NCPE Assessment Process Ongoing
Rapid review commissioned 08/02/2021
Rapid review completed 03/03/2021
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 24/03/2021
Pre-submission consultation with Applicant 21/04/2021
Full submission received from Applicant 21/01/2022
Current Status Full submission received from Applicant